Grace Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Loss and Comprehensive Loss
| Three months ended | Six months ended | |||
|---|---|---|---|---|
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |
| (Expressed in thousands, except share and per share data) | $ | $ | $ | $ |
| Operating expenses | ||||
| Research and development expenses, net of government assistance | (2,976) | (460) | (5,684) | (1,555) |
| General and administrative | (1,855) | (1,632) | (4,109) | (3,506) |
| Restructuring cost | — | — | — | (1,485) |
| Loss from operating activities | (4,831) | (2,092) | (9,793) | (6,546) |
| Foreign exchange gain (loss) | 13 | (13) | 5 | (5) |
| Change in fair value of derivative warrant liabilities | 362 | (1,826) | 1,756 | (1,826) |
| Interest and other income, net | 172 | 212 | 407 | 346 |
| Total other income (expenses), net | 547 | (1,627) | 2,168 | (1,485) |
| Loss before income tax benefit | (4,284) | (3,719) | (7,625) | (8,031) |
| Income tax benefit | 852 | 446 | 1,576 | 735 |
| Net loss and total comprehensive loss | (3,432) | (3,273) | (6,049) | (7,296) |
| Basic and diluted loss per share | (0.30) | (0.43) | (0.53) | (0.97) |
| Weighted average number of shares outstanding | 11,506,234 | 7,552,677 | 11,506,234 | 7,494,425 |
(Formerly ACASTI PHARMA INC)
Condensed Consolidated Statements of Shareholders’ Equity
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.